ImageneBio, Inc. IMA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
ImageneBio, Inc. (IMA) is a healthcare company listed in the US with a market value of about $43M. In fiscal year 2025 it had revenue of $800000 and net income of -$45M, a net margin of -5668.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -39% a year, a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About ImageneBio
ImageneBio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $9M in 2020 to $800000 in 2025, a decline of about 38.6% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 444% over three years (dilution for shareholders). It spends 3566% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $800000 | $4M | $9M | $16M | $31M | $9M |
| Net income | -$45M | -$37M | -$68M | -$69M | -$34M | -$44M |
| Free cash flow | — | — | -$80M | -$76M | -$62M | -$39M |
| EPS (diluted) | $-9.64 | $-22.10 | $-65.87 | $-76.78 | $-49.30 | $-646.58 |
| Net margin | -5668.6% | -1044.8% | -744.2% | -440.3% | -110.1% | -481.4% |
| ROIC | -35.3% | — | — | -46.4% | -12.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is ImageneBio stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does ImageneBio pay a dividend?
Not currently.
Is ImageneBio a good stock to buy?
We do not give buy or sell advice. ImageneBio scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.